- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ACA on Trial: 'The Mandate'
Next week the Supreme Court will hear oral arguments on the constitutionality of the healthcare reform law, just days after the two-year anniversary of the Affordable Care Act (ACA). In a three-part series, MedPage Today takes a closer look at the main arguments for and against the law.
First up: The individual mandate. Later in the week, we'll explore whether the mandate can be severed from the rest of the law, followed by an analysis of the constitutional issues involved in the ACA's expansion of Medicaid.
President Obama's landmark healthcare reform law contains a provision that many consider its linchpin: a requirement that nearly every U.S. citizen have health insurance or else pay a penalty.
Read the full story: http://hcp.lv/GMOjF4
Source: MedPage Today
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
